Norvaline.

Arginase competes with nitric oxide synthase for arginine and diverts it into the urea cycle. Norvaline inhibits arginase, so more of a co-dosed arginine load stays available to the nitric oxide pathway.

Citrulline is converted to arginine in the kidney and raises plasma arginine more reliably than oral arginine does. Norvaline acts on the other side of that same pool by inhibiting arginase, the enzyme that clears arginine into the urea cycle.

Norvaline slows arginase, the route that pulls arginine toward ornithine and urea. Less diversion leaves more arginine for nitric oxide synthase, based on enzyme and cell work.

Citrulline is recycled into arginine inside cells while norvaline slows the arginase step that breaks arginine down. They act at opposite ends of one cycle.

The citrulline portion regenerates arginine intracellularly and norvaline limits arginase loss of that arginine. Malate feeds the citric acid cycle in the same working tissue.

This salt delivers arginine, and norvaline's arginase inhibition applies to it unchanged. Less of the delivered arginine is pulled into the urea route.

Norvaline is valine without the side-chain branch, so it competes for the same transporters. Together they compete rather than add.

Both are neutral aliphatic amino acids using the system L carrier. A large dose of one reduces uptake of the other.

Nitrate is reduced to nitrite and on to nitric oxide without the arginine enzyme. It gives a second route to the same output norvaline supports.

Beetroot nitrate reaches nitric oxide by a reduction route independent of arginine. That complements arginase inhibition on the arginine side.

Ascorbate holds tetrahydrobiopterin in its reduced form so nitric oxide synthase stays coupled. Substrate sparing works only if the enzyme is coupled.

Pine bark polyphenols raise endothelial nitric oxide synthase activity while norvaline works on substrate supply. Those are separate control points on one output.

Ornithine is the product arginase makes from arginine, so supplying ornithine directly sidesteps the step norvaline slows. Taken together the two push in different directions on the same node: one restrains the enzyme, the other tops up its product. Formulators combining them should be clear which effect they are after.

Arginase is a binuclear manganese metalloenzyme and needs manganese at its active site to work at all. Norvaline acts on the same enzyme as a competitive substrate analogue. The two therefore meet at one protein from opposite sides, manganese as the requirement and norvaline as the brake.

Lysine and arginine are both cationic amino acids carried by the y+ system, so a large lysine dose competes with arginine for uptake. That works against the point of an arginase-sparing strategy, which is to keep more arginine available. Separating the two doses in time is the straightforward answer.

Glutamine feeds enterocyte citrulline production, and circulating citrulline is what the kidney converts back to arginine. It therefore raises the arginine pool from upstream while norvaline acts on the enzyme that drains it. The two routes are independent and do not compete for the same carrier.

Norvaline is a straight-chain structural relative of the branched-chain amino acids and shares the large neutral amino acid carrier with them. A full branched-chain dose taken at the same time competes for that carrier. This is a timing consideration rather than a reason to avoid either.

Endogenous creatine synthesis consumes arginine through arginine-glycine amidinotransferase, which is one of the larger ongoing demands on the arginine pool. Supplying creatine reduces that demand and leaves more arginine in circulation. This works on the arginine budget from a different angle than an arginase-directed compound does.

Glycine is the co-substrate with arginine in the first committed step of creatine synthesis, so the two are consumed together. Anything that changes arginine availability changes the throughput of that reaction. Glycine is also cheap enough that it commonly appears alongside arginine-directed ingredients for this reason.

Pyridoxal-5-phosphate is the cofactor for ornithine aminotransferase and for the transaminases that handle straight-chain and branched-chain amino acids, norvaline among them. B6 status therefore sits underneath how quickly norvaline itself is metabolised. The relationship is cofactor chemistry rather than a measured combination effect.

Aged garlic extract is studied for effects on vascular tone through nitric-oxide-adjacent pathways, and norvaline is aimed at the same pathway from the substrate side. No trial has given the two together in humans. The pairing is mechanistic reasoning, not a measured combination.